Patents by Inventor Ziqing QIAN

Ziqing QIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240358845
    Abstract: Provided herein are compounds that include a cyclic cell penetrating peptide, a therapeutic moiety and a modulatory peptide, wherein the modulatory peptide modulates the tissue distribution and/or retention of the compound in vivo. Also provide herein are methods of modulating tissue distribution and/or retention of intracellular therapeutics using the aforementioned compounds.
    Type: Application
    Filed: May 9, 2022
    Publication date: October 31, 2024
    Inventors: Ziqing Qian, Patrick Dougherty, Mahboubeh Kheirabadi, Haoming Liu, Xiulong Shen, Xiang Li
  • Publication number: 20240360174
    Abstract: Disclosed are cell-penetrating cyclic peptides. The peptides can be used to deliver peptides and other biologically active moieties into cells. Formulations containing the cell-penetrating cyclic peptides are also described.
    Type: Application
    Filed: June 26, 2024
    Publication date: October 31, 2024
    Inventors: Dehua PEI, Ziqing QIAN
  • Publication number: 20240247259
    Abstract: Compounds that include a cyclic cell penetrating peptide and a therapeutic moiety that modulates polyadenylation of a gene transcript. The therapeutic moiety may be an antisense compound (AC) that binds a target gene transcript. The AC may bind to at least a portion of a polyadenylation signal element (PSE) or may bind in sufficiently close proximity to the PSE to modulate polyadenylation of the target gene transcript. Methods include administering the aforementioned compounds to cells or subjects to modulate diseases or conditions.
    Type: Application
    Filed: May 9, 2022
    Publication date: July 25, 2024
    Inventors: Xiulong SHEN, Xiang LI, Ziqing QIAN, Natarajan SETHURAMAN, Haoming LIU
  • Publication number: 20240245790
    Abstract: The present disclosure is directed to cell penetrating peptides, including cyclic cell penetrating peptides with high cytosolic delivery efficiency and reduced toxicity that are able to effectively deliver cargo inside a cell to treat a variety of conditions and diseases.
    Type: Application
    Filed: November 9, 2023
    Publication date: July 25, 2024
    Inventors: Ziqing Qian, Patrick Dougherty, Mahboubeh Kheirabadi, Haoming Liu, Xiulong Shen
  • Patent number: 11987821
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: May 21, 2024
    Assignee: Entrada Therapeutics, Inc.
    Inventors: Natarajan Sethuraman, Jason Ruth, Louis A. Tartaglia, Dehua Pei, Ziqing Qian
  • Publication number: 20240101509
    Abstract: Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.
    Type: Application
    Filed: October 31, 2023
    Publication date: March 28, 2024
    Inventors: Dehua PEI, George APPIAH KUBI, Ziqing QIAN
  • Patent number: 11878046
    Abstract: Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: January 23, 2024
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Patent number: 11814341
    Abstract: Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: November 14, 2023
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Dehua Pei, George Appiah Kubi, Ziqing Qian
  • Publication number: 20230312653
    Abstract: The present disclosure is directed to cell penetrating peptides, including cyclic cell penetrating peptides with high cytosolic delivery efficiency and reduced toxicity that are able to effectively deliver cargo inside a cell to treat a variety of conditions and diseases.
    Type: Application
    Filed: March 30, 2023
    Publication date: October 5, 2023
    Inventors: Patrick Dougherty, Ziqing Qian, Mahboubeh Kheirabadi
  • Publication number: 20230097585
    Abstract: The present disclosure provides the synthesis of phosphorodiamidate morpholino oligomers (PMOs) in high purity, yield, and efficiency from Fmoc-protected morpholino monomers, e.g., Fmoc morpholino monomer G.
    Type: Application
    Filed: June 10, 2022
    Publication date: March 30, 2023
    Inventors: Kyle A. Totaro, Ziqing Qian
  • Publication number: 20230027739
    Abstract: Degradation compounds include a cyclic cell penetrating peptide (cCPP) and a degradation construct. The degradation construct includes a degradation moiety and a targeting moiety. The targeting moiety binds a target protein. When the targeting moiety is bound to the target protein, the degradation moiety mediates degradation of the target protein. The cCPP facilitates transfer of the degradation construct into a cell. The degradation compound may further include an exocyclic peptide to enhance endosomal escape of the compound or degradation construct once inside the cell.
    Type: Application
    Filed: May 9, 2022
    Publication date: January 26, 2023
    Inventors: Natarajan SETHURAMAN, Patrick DOUGHERTY, Byung-Kwon CHOI, Nicholas Emerson LONG, Ziqing QIAN
  • Publication number: 20230020092
    Abstract: Provided herein are compounds comprising cyclic cell penetrating peptides and antisense compounds. Also provided herein are methods of modulating splicing, inhibiting or regulating translation, mediating degradation, blocking expansions of nucleotide repeats, and treating disease using the aforementioned compounds.
    Type: Application
    Filed: December 21, 2020
    Publication date: January 19, 2023
    Inventors: Ziqing Qian, Xiang Li, Mahboubeh Kheirabadi, Mohanraj Dhanabal, Haoming Liu, Xiulong Shen, Kimberli Kamer, Natarajan Sethuraman
  • Publication number: 20220306693
    Abstract: Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-haripin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 29, 2022
    Inventors: Dehua PEI, Ziqing QIAN
  • Publication number: 20220177523
    Abstract: Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Inventors: Dehua PEI, Ziqing QIAN
  • Patent number: 11352394
    Abstract: Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-hairpin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: June 7, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Patent number: 11351222
    Abstract: Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 7, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Publication number: 20220160819
    Abstract: Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
    Type: Application
    Filed: November 30, 2021
    Publication date: May 26, 2022
    Inventors: Dehua PEI, Ziqing QIAN
  • Patent number: 11266713
    Abstract: Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: March 8, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Publication number: 20220033787
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Application
    Filed: October 6, 2021
    Publication date: February 3, 2022
    Inventors: Natarajan SETHURAMAN, Jason RUTH, Louis A. TARTAGLIA, Dehua PEI, Ziqing QIAN
  • Patent number: 11225506
    Abstract: Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: January 18, 2022
    Assignee: Entrada Therapeutics, Inc.
    Inventors: Dehua Pei, Ziqing Qian